Article
Pharmacology & Pharmacy
Liang Huang, Wei Wei, Xiaomei Huang, Xuejing Li, Haisha Liu, Lanlan Gui, Jinping Jiang, Linfei Wan, Xiangxiang Zhou, Jingsong Ding, Xuehua Jiang, Bikui Zhang, Ke Lan
Summary: This study investigated the effects of high-fat diets on the pharmacokinetics of ursodeoxycholic acid (UDCA) and the circulating bile salt levels. The results showed that high-fat diets delayed the absorption of UDCA but enhanced its metabolite. However, the high-fat diets also led to an increase in circulating hydrophobic bile salts, which may limit the effectiveness of UDCA.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Silvia Marchiano, Michele Biagioli, Rosalinda Roselli, Angela Zampella, Cristina Di Giorgio, Martina Bordoni, Rachele Bellini, Ginevra Urbani, Elva Morretta, Maria Chiara Monti, Eleonora Distrutti, Stefano Fiorucci
Summary: The study compared the pharmacological effects of UDCA and norUDCA in a mouse model of NAFLD/NASH, finding that both protected against liver steatosis and fibrosis development, improved lipid metabolism and insulin sensitivity, with UDCA acting as a GPBAR1 agonist, while norUDCA had no effect on GPBAR1 signaling.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
(2022)
Review
Gastroenterology & Hepatology
Ilaria Lenci, Martina Milana, Alessandro Signorello, Giuseppe Grassi, Leonardo Baiocchi
Summary: The biliary tract is no longer considered as a passive system. Recent research has demonstrated the important role of biliary epithelia in bile formation. Bile acids, the most abundant organic molecules in bile, were initially seen as natural detergents but are now recognized as important signaling molecules. This review focuses on the effects of different bile acids on the biliary epithelia, particularly secondary bile acids derived from bacterial manipulation. Understanding the interaction between bile acids and cholangiocytes may contribute to better treatments for cholestatic diseases.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Lauren E. E. Lynch, Amy B. B. Hair, Krishnakant G. G. Soni, Heeju Yang, Laura A. A. Gollins, Monica Narvaez-Rivas, Kenneth D. R. Setchell, Geoffrey A. A. Preidis
Summary: Cholestasis refers to impaired bile flow from the liver to the intestine. In neonates, cholestasis causes poor growth and may progress to liver failure and death. This study examined the development of the liver-gut-microbiome axis and the effects of cholestasis on this development in extremely preterm infants. The results showed that cholestasis interrupts the development of the secondary bile acid biosynthesis pathway and bile salt hydrolase genes, which are important for normal bile flow.
Article
Biochemistry & Molecular Biology
Gianmaria Miolo, Angela Buonadonna, Simona Scalone, Davide Lombardi, Lara Della Puppa, Agostino Steffan, Giuseppe Corona
Summary: Specific bile acid metabolic profiles may be associated with the prognosis of mSTS patients, while prognostic factors for mSTS are currently very limited.
Article
Biology
Josue Orozco-Aguilar, Franco Tacchi, Francisco Aguirre, Mayalen Valero-Breton, Mauricio Castro-Sepulveda, Felipe Simon, Claudio Cabello-Verrugio
Summary: Background: Skeletal muscle generates force and movements and maintains posture. Under pathological conditions, muscle fibers suffer an imbalance in protein synthesis/degradation. This event causes muscle mass loss and decreased strength and muscle function, a syndrome known as sarcopenia. Recently, our laboratory described secondary sarcopenia in a chronic cholestatic liver disease (CCLD) mouse model. Interestingly, the administration of ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is an effective therapy for cholestatic hepatic alterations. However, the effect of UDCA on skeletal muscle mass and functionality has never been evaluated, nor the possible involved mechanisms.
BIOLOGICAL RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Nahum Mendez-Sanchez, Carlos E. Coronel-Castillo, Ana L. Ordonez-Vazquez
Summary: Cholestasis is a condition characterized by decreased bile flow, affecting the intrahepatic and extrahepatic biliary tree. It can lead to complications such as cirrhosis, liver failure, malignancies, bone disease, and nutritional deficiencies. Understanding the treatment options for cholestatic liver diseases is important due to the impact on mortality and quality of life. This review provides a comprehensive overview of the pathophysiology of cholangiopathies and aims to guide clinicians in the safe and effective treatment based on current evidence.
Article
Chemistry, Medicinal
Xiaosu Zou, Chang Liu, Congcong Li, Rong Fu, Wei Xu, Hongzhu Bian, Xun Dong, Xiaozhen Zhao, Zhenye Xu, Jinghua Zhang, Zhengwu Shen
Summary: A series of dihydroartemisinin derivatives with anti-proliferation activity against cancer cells were synthesized, and the dihydroartemisinin-ursodeoxycholic acid conjugate showed the most potent activity. In vivo experiments confirmed its effectiveness in suppressing tumor growth in different cell models.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Immunology
Colleen M. Pike, John Tam, Roman A. Melnyk, Casey M. Theriot
Summary: CDI is a highly inflammatory disease, and alternative therapies are needed. Conjugation of bile acids may have different therapeutic mechanisms against C. difficile and host during CDI.
INFECTION AND IMMUNITY
(2022)
Article
Multidisciplinary Sciences
N. Carrossini, N. Meireles Da Costa, E. Andrade-Barreto, V. P. L. Sousa, P. Nicolau-Neto, P. T. Souza-Santos, G. R. Mansur, L. Wernersbach, P. T. Bozza, J. P. B. Viola, Luis Felipe Ribeiro Pinto
Summary: Esophageal cancer presents two main histological subtypes, with ESCC mainly associated with tobacco and alcohol abuse, and EAC and BE linked to obesity and chronic GERD. Obesity triggers LD accumulation in non-adipose tissues, which may contribute to the production and action of inflammatory mediators, thus promoting the genesis and progression of BE and EAC.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Elisabetta Melloni, Elena Marchesi, Lorenzo Preti, Fabio Casciano, Erika Rimondi, Arianna Romani, Paola Secchiero, Maria Luisa Navacchia, Daniela Perrone
Summary: Chenodeoxycholic acid and ursodeoxycholic acid were conjugated with paclitaxel to improve its ability to enter cancer cells, while exhibiting lower toxicity on healthy cells.
Article
Pharmacology & Pharmacy
Fangfang Xu, Jun Wang, Pan Wang, Tao Hou, Han Zhou, Yaopeng Zhao, Jixia Wang, Yanfang Liu, Xinmiao Liang
Summary: Ursodeoxycholic acid (UDCA) is a safe and effective bile acid for the treatment of non-alcoholic fatty liver disease (NAFLD). This study identified that UDCA acts as an agonist of the free fatty acid receptor 4 (FFA4), which plays a protective role in NAFLD treatment.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Toxicology
Jingxuan Wang, Wouter Bakker, Weijia Zheng, Laura de Haan, Ivonne M. C. M. Rietjens, Hans Bouwmeester
Summary: This study found that deoxynivalenol (DON) inhibits the reabsorption of bile acids in the intestines by reducing the expression of bile acid transporters. This has an impact on the metabolism of bile acids in the intestines. The results of this study provide new insights into the hazards of DON exposure.
ARCHIVES OF TOXICOLOGY
(2022)
Article
Medicine, General & Internal
Gal Hershkovitz, Yael Raz, Ilana Goldinger, Ariel Many, Liran Hiersch, Rimon Eli
Summary: Intrahepatic cholestasis of pregnancy (ICP) is characterized by elevated total bile acids (TBA). It is unclear why some fetuses are more prone to the hazardous effect of bile acids (BA) over the others. We aimed to compare TBA levels in umbilical vein and artery to maternal TBA in women with ICP. The study included 18 women and 23 fetuses, and we found that the TBA level in umbilical vein was significantly lower compared to maternal TBA level.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Lu Zhang, Binyu Sun, Xi Zhou, QiongQiong Wei, Sicheng Liang, Gang Luo, Tao Li, Muhan Lu
Summary: This article briefly describes the etiology and clinical significance of intestinal metaplasia in Barrett's esophagus, as well as its impact on diagnosis, monitoring, and treatment according to different guidelines. The basis for endoscopic diagnosis and identification techniques of goblet cells in Barrett's esophagus are explored, along with current treatment methods related to the condition.
FRONTIERS IN ONCOLOGY
(2021)